Suppr超能文献

合成、结构-活性关系及 13-正辛基小檗碱衍生物的体外抗分枝杆菌活性评价。

Synthesis, structure-activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives.

机构信息

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

出版信息

Eur J Med Chem. 2012 Jun;52:151-8. doi: 10.1016/j.ejmech.2012.03.012. Epub 2012 Mar 21.

Abstract

Twenty-eight new 13-n-octylberberine derivatives were synthesized and evaluated for their activities against drug-susceptible Mycobacterium tuberculosis (M. tuberculosis) strain H(37)Rv. Among these compounds, compound 16e was the most effective anti-tubercular agent with a MIC value of 0.125 μg/mL. Importantly, compound 16e exhibited more potent effect against rifampicin (RIF)- and isoniazid (INH)-resistant M. tuberculosis strains than both RIF and INH, suggesting a new mechanism of action. Therefore, it has been selected as a drug candidate for further investigation, or as a chemical probe for identifying protein target and studying tuberculosis biology. We consider 13-n-octylberberine analogs to be a promising novel class of antituberculars against multi-drug-resistant (MDR) strains of M. tuberculosis.

摘要

合成了 28 种新型 13-正辛基小檗碱衍生物,并评估了它们对药敏结核分枝杆菌(M. tuberculosis)H(37 )Rv 株的活性。在这些化合物中,化合物 16e 是最有效的抗结核剂,MIC 值为 0.125μg/mL。重要的是,化合物 16e 对利福平(RIF)和异烟肼(INH)耐药结核分枝杆菌菌株的作用比 RIF 和 INH 更强,提示其具有新的作用机制。因此,它已被选为进一步研究的候选药物,或作为鉴定蛋白靶标和研究结核病生物学的化学探针。我们认为 13-正辛基小檗碱类似物是一种有前途的新型抗结核药物,可用于治疗耐多药(MDR)结核分枝杆菌菌株。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验